Once-weekly GLP-1R agonists: Moving the goal posts

Abd A. Tahrani; Srikanth Bellary; Anthony H. Barnett

doi:10.1016/S2213-8587(18)30049-4

Once-weekly GLP-1R agonists: Moving the goal posts

Abd A. Tahrani^*, Srikanth Bellary, Anthony H. Barnett

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

294 Downloads (Pure)

Abstract

Glucagon like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes were first introduced to Europe and the USA in 2005.1 Since then, these compounds have become well-established treatment options in the management of type 2 diabetes.2 GLP-1 R agonists have several attractive features including potent and sustained glucose lowering, low risk of hypoglycaemia because of their glucose-dependent effects on insulin and glucagon secretion, sustained weight loss, and a favourable effect on cardiovascular risk factors together with reduction in cardiovascular event rates (liraglutide and semaglutide).

Original language	English
Pages (from-to)	260-261
Journal	The Lancet Diabetes and Endocrinology
Volume	6
Issue number	4
DOIs	https://doi.org/10.1016/S2213-8587(18)30049-4
Publication status	Published - 31 Jan 2018

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2213-8587(18)30049-4

Tahrani_et_al_Once-weekly_GLP-1_receptor_The_Lancet_Diabetes_and_Endocrinology_2018
Checked for eligibility: 26/03/2018 Copyright © 2018 Elsevier Limited except certain content provided by third parties http://www.thelancet.com/journals/landia/article/PIIS2213-8587(18)30049-4/fulltext DOI: https://doi.org/10.1016/S2213-8587(18)30049-4
Accepted author manuscript, 95.2 KBLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Cite this

@article{5e28464a5abd48b8a78d293793e5c021,

title = "Once-weekly GLP-1R agonists: Moving the goal posts",

abstract = "Glucagon like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes were first introduced to Europe and the USA in 2005.1 Since then, these compounds have become well-established treatment options in the management of type 2 diabetes.2 GLP-1 R agonists have several attractive features including potent and sustained glucose lowering, low risk of hypoglycaemia because of their glucose-dependent effects on insulin and glucagon secretion, sustained weight loss, and a favourable effect on cardiovascular risk factors together with reduction in cardiovascular event rates (liraglutide and semaglutide).",

author = "Tahrani, {Abd A.} and Srikanth Bellary and Barnett, {Anthony H.}",

year = "2018",

month = jan,

day = "31",

doi = "10.1016/S2213-8587(18)30049-4",

language = "English",

volume = "6",

pages = "260--261",

journal = "The Lancet Diabetes and Endocrinology",

issn = "2213-8587",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Once-weekly GLP-1R agonists

T2 - Moving the goal posts

AU - Tahrani, Abd A.

AU - Bellary, Srikanth

AU - Barnett, Anthony H.

PY - 2018/1/31

Y1 - 2018/1/31

N2 - Glucagon like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes were first introduced to Europe and the USA in 2005.1 Since then, these compounds have become well-established treatment options in the management of type 2 diabetes.2 GLP-1 R agonists have several attractive features including potent and sustained glucose lowering, low risk of hypoglycaemia because of their glucose-dependent effects on insulin and glucagon secretion, sustained weight loss, and a favourable effect on cardiovascular risk factors together with reduction in cardiovascular event rates (liraglutide and semaglutide).

AB - Glucagon like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes were first introduced to Europe and the USA in 2005.1 Since then, these compounds have become well-established treatment options in the management of type 2 diabetes.2 GLP-1 R agonists have several attractive features including potent and sustained glucose lowering, low risk of hypoglycaemia because of their glucose-dependent effects on insulin and glucagon secretion, sustained weight loss, and a favourable effect on cardiovascular risk factors together with reduction in cardiovascular event rates (liraglutide and semaglutide).

UR - http://www.scopus.com/inward/record.url?scp=85041621869&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(18)30049-4

DO - 10.1016/S2213-8587(18)30049-4

M3 - Article

AN - SCOPUS:85041621869

SN - 2213-8587

VL - 6

SP - 260

EP - 261

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

IS - 4

ER -

Once-weekly GLP-1R agonists: Moving the goal posts

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this